Why TG Therapeutics Stock Is Back in Focus After Q2 Earnings

TG Therapeutics (TGTX) drew fresh attention after reporting second quarter 2026 results that combined higher revenue with lower net income, while also lifting full year revenue guidance to about US$950 million.

TG Therapeutics shares trade at US$47.94, with the stock down about 13% over the past month but still showing strong momentum with a 64% year to date share price return and a very large 3 year total shareholder return that reflects how much long term holders have benefited. Recent earnings, higher full year revenue guidance and upcoming conference appearances have kept TG Therapeutics in the spotlight as investors reassess both growth prospects and risk.

If this kind of biotech story has your attention, it can be useful to see what else is moving in the sector by checking out our screener of 44 healthcare AI stocks

The recent pullback in TG Therapeutics after strong share gains and higher revenue guidance leaves a simple tension: Is the stock now tracking the underlying business, or are you mostly watching sentiment swing around the story?

Most Popular Narrative: 7.3% Undervalued

At a last close of $47.94 versus a narrative fair value of $51.71, TG Therapeutics is framed as modestly undervalued, with that view resting heavily on how BRIUMVI ramps from here.

The upcoming launch of subcutaneous BRIUMVI and expanded market access are set to drive substantial long-term revenue and sales growth. Strong commercial execution, demographic trends, and a lean operational model create pathways for ongoing market penetration and margin improvement.

Curious what sits behind that confidence in TG Therapeutics. The narrative leans on rapid top line expansion, shifting product mix and a different earnings profile a few years out. The key is how those moving parts line up in the valuation math.

Result: Fair Value of $51.71 (UNDERVALUED)

However, the TG Therapeutics story still leans heavily on BRIUMVI, so any competitive pressure or pricing pushback could quickly challenge that 7.3% undervalued narrative.

Next Steps

If the TG Therapeutics story so far feels balanced between promise and concern, now is a good time to look under the hood yourself. Review the full breakdown of 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond TG Therapeutics?

If you only stop with TG Therapeutics, you could miss other opportunities that fit your style even better. Let the data surface ideas you might not spot on your own.

• Target dependable cash flows and capital strength by scanning companies in the solid balance sheet and fundamentals stocks screener (49 results).
• Hunt for potential mispricing by reviewing companies highlighted in the screener containing 18 high quality undiscovered gems.
• Prioritise stability and fewer surprises by filtering for companies identified in the 88 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.